# A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

> **NCT03427710** · PHASE1 · COMPLETED · sponsor: **Civi Biopharma, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** CiVi007
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03427710
- **Lead sponsor:** Civi Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-07
- **Primary completion:** 2020-02-14
- **Final completion:** 2020-08-18
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427710, "A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03427710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*